Edited by: Yiping Shen, Harvard Medical School, United States
Reviewed by: Ahmad Mustafa Metwalley, Women’s Health Fertility Clinic, Saudi Arabia; Diao Feiyang, Nanjing Medical University, China
*Correspondence: Mei Li,
†These authors have contributed equally to this work and share first authorship
This article was submitted to Reproduction, a section of the journal Frontiers in Endocrinology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
To explore the clinical application value of half-ICSI treatment for infertility in assisted reproductive technology.
A retrospective analysis of 1130 half-ICSI treatments was conducted at the Affiliated Reproductive Hospital of Shandong University from January 2011 to December 2015. Patients with low fertilization rates in previous cycles, primary infertility for >5 years with unexplained reason, or secondary infertility for >5 years without fallopian tube factor were involved in this study. The 2PN rate, high-quality embryo rate, oocyte utilization rate, and clinical outcomes were compared between IVF insemination group (IVF group) and ICSI insemination group (ICSI group). The clinical outcome of half-ICSI insemination treatment, grouped according primary and secondary infertility, was also analyzed.
Compared with IVF, ICSI resulted in a significantly higher 2PN rate (74.8% vs. 62.9%), high-quality embryo rate (54.6% vs. 51.7%), and oocyte utilization rate (35.9% vs. 32.8%; P<0.05). Among the 884 fresh-embryo transfer cycles, there were no notable differences in clinical pregnancy rate, live birth rate, or neonatal abnormality rate between the IVF and ICSI groups. Among the 792 primary infertility cycles, ICSI resulted in a significantly higher 2PN rate, high-quality embryo rate, and oocyte utilization rate compared with IVF (75.3% vs. 62.4%, 54.3% vs. 50.8%, 36.4% vs. 32.6%, P<0.05). For the 338 secondary infertility cycles, ICSI resulted in a significantly higher 2PN rate (73.6% vs. 63.9%, P<0.05) compared with IVF, but there were no notable differences in other laboratory results. Moreover, the biochemical pregnancy rate of the ICSI group was significantly lower than for IVF in secondary infertility cycles (49.3% vs. 65.6%; P<0.05). A total of 89 cycles (7.9%) with complete IVF fertilization failure showed a low second polar body (2PB) rate (33.6%) after a 5-h short-time fertilization period, including 34 cycles (3.0%) with no 2PB oocytes observed in the IVF group.
ICSI insemination improved laboratory results compared with IVF insemination, however, fresh-embryo transfer of ICSI originated embryos did not improve clinical pregnancy and live birth rates. Rescue ICSI has been successfully applied in clinical IVF insemination to avoid fertilization failure. Therefore, as an extra intervention, it is suggested that ICSI be used judiciously.
Oocyte fertilization is a critical step in assisted reproductive technology (ART). A low fertilization rate or complete fertilization failure may occur in some infertility treatment cycles, and the subsequent repeated assisted pregnancy therapy may result in psychological and economic pressure on patients. The incidence of complete fertilization failure ranges from 10% to 20% (
Recently, increasing evidence has shown the positive role of half-ICSI in ART. Half-ICSI results in more high-quality embryos for transfer and improves the rate of pregnancy for patients with a high risk of fertilization failure (
The purpose of this study was to further evaluate the effect of half-ICSI treatment in ART. We conducted a retrospective analysis of 1130 half-ICSI insemination treatments at our center from January 2011 to December 2015. We evaluated the effects of different insemination methods on the clinical outcomes of these patients, in order to provide a reference for more focused clinical treatment in the future.
A total of 1130 half-ICSI patients were enrolled in this study from January 2011 to December 2015. Half-ICSI treatment was given to patients with the following infertility backgrounds: patients with a fertilization rate between 30% and 50% in previous IVF cycles; patients with primary unexplained infertility for >5 years, or secondary infertility for >5 years without fallopian tube problems. All the patients involved in half-ICSI treatments had at least eight oocytes retrieved and the semen profile was normal.
All patients underwent controlled ovarian hyperstimulation(COH). Ovarian stimulation protocols included controlled ovarian hyperstimulation after gonadotropin-releasing hormone (GnRH) agonist down-regulation or an antagonist protocol. Recombinant follicle-stimulating hormone (rFSH, PUREGON; MSD Organon, Oss, Netherlands) was started on day 1–3 of the menstrual cycle. The dose adjustment of gonadotropin, monitoring of the ovarian response, and the timing for triggering the final oocyte maturation during ovarian stimulation was performed under the discretion of the supervising clinician. Oocyte retrieval was performed 34–36 h after the administration of human chorionic gonadotropin (hCG) at a dose of 4000–10 000 IU.
Oocytes were inseminated approximately 3–6 h after follicular aspiration using a conventional insemination method and ICSI. The oocytes were divided into two groups equally and randomly. One group underwent IVF insemination and the other group underwent ICSI insemination. If the total number of oocytes is odd, one more oocyte was divided into the ICSI group. Short-time insemination in the IVF group was used, but no rescue ICSI was performed on the oocytes. Sequential culture media from Vitrolife (G-IVF, G1 and G2; Scandinavian IVF Science, Goteborg, Sweden) were used in all steps. Embryos were cultured separately in pre-equilibrated culture media overlaid with mineral oil. The culture dishes were housed in 37 °C tri-gas tabletop incubators (K-system, Denmark) containing 5% O2 and 6% CO2, balanced with N2. Two or three high-quality embryos were selected for fresh transfer on day 3. For patients who could only accept a single embryo transfer, a single blastocyst was selected and transferred on day 5. High-quality embryos in the IVF group were selected for transfer as a priority. High-quality embryos in the ICSI group were selected for transfer if there was only one or no high-quality embryo in the IVF group. Supernumerary embryos were cultured for blastocyst cryopreservation. Morphologic criteria were used for day-3 embryo scoring based on the amount of anucleate fragments expelled during early cleavage, and on developmental speed (
In both the ICSI insemination group (ICSI group) and the IVF insemination group (IVF group), the 2PN rate of matured oocytes, the high-quality day-3 embryo rate, and the utilized oocyte rate, including embryos transferred and embryos vitrified, were calculated.
When embryos originated from different insemination groups in fresh-embryo transfer cycles, the clinical results were calculated separately. All the fresh-embryo transfer cycles were divided into three groups: the IVF group, where IVF insemination embryos were transferred; the ICSI group, where ICSI insemination embryos were transferred; and the IVF plus ICSI group, where IVF embryos and ICSI embryos were both transferred at the same time. A serum hCG level>10 IU/L at 14 days after embryo transfer was diagnosed as a biochemical pregnancy and cardiac activity 7 weeks after embryo transfer was defined as a clinical pregnancy. Live birth was defined as the delivery of a live-born infant at≥28 weeks of gestation. Preterm birth rate and neonatal abnormalities were also calculated.
All analyses were performed using SPSS Statistics (version 22.0). Statistical analyses were conducted using the t-test and chi-square test. P-value was bilateral and P<0.05 was considered statistically significant. Statistical analysis was performed using a χ2 test. A P-value<0.05 was considered statistically significant.
Patient characteristics are listed in
Characteristics of the 1130 half-ICSI patients.
| Characteristic | No. cycles | Value |
|---|---|---|
| Age (y) (mean ± STD) | 32.43 ± 4.05 | |
| Infertility factors | ||
| Primary | 792 (70.1%) | |
| Secondary | 338 (30.0%) | |
| Regimen of ovarian hyperstimulation | ||
| super long-term protocol | 12 (1.1%) | |
| long-term protocol | 954 (84.4%) | |
| short-term protocol | 104 (9.2%) | |
| Antagonist protocol | 41 (3.6%) | |
| other protocol | 16 (1.4%) | |
| microstimulation protocol | 3 (0.3%) | |
| Result of treatment | ||
| Fresh embryo-transfer cycles | 884 (78.2%) | |
| Cryopreserved cycles | 202 (17.9%) | |
| Complete abandoned cycles | 45 (4.0%) | |
The 2PN rate, high-quality embryo rate, and utilized oocyte rate of ICSI embryos were significantly higher than for IVF embryos (74.8%vs. 62.9%, 54.6%vs. 51.7%, 35.9%vs. 32.8%, P<0.05;
Embryo outcome of the total 1130 half-ICSI patients.
| Characteristic | IVF | ICSI |
|---|---|---|
| Matured oocytes: no. | 6728 | 7014 |
| 2PN: no. (%) | 4230 (62.9) | 5245 (74.8)* |
| High-quality embryo: no. (%) | 2185 (51.7) | 2862 (54.6)* |
| Transferred embryo: no. | 978 | 782 |
| Vitrified embryo: no. | 1227 | 1737 |
| Utilized oocytes: no. (%) | 2205 (32.8) | 2519 (35.9)* |
Values are presented as number (%).
*P <0.05 ICSI compared to IVF groups.
Embryo outcome of the 792 primary infertility and 338 secondary infertility patients.
| Primary infertility | Secondary infertility | |||
|---|---|---|---|---|
| Characteristic | IVF | ICSI | IVF | ICSI |
| Matured oocytes: no. | 4752 | 4947 | 1976 | 2067 |
| 2PN: no. (%) | 2967 (62.4) | 3724 (75.3)* | 1264 (63.9) | 1521 (73.6)* |
| High-quality embryo: no. (%) | 1507 (50.8) | 2021 (54.3)* | 678 (53.7) | 841 (55.3) |
| Transferred embryo: no. | 650 | 547 | 328 | 235 |
| Vitrified embryo: no. | 897 | 1256 | 330 | 481 |
| Utilized oocytes: no. (%) | 1547 (32.6) | 1803 (36.4)* | 658 (33.3) | 716 (34.6) |
Values are presented as number (%).
*P <0.05 ICSI compared to IVF groups.
A total of 884 patients underwent fresh embryo transfer. Biochemical pregnancy rates of the ICSI group and IVF plus ICSI group were both lower than for the IVF group (53.6%vs. 64.2%, 55.5%vs. 64.2%, P<0.05;
Clinical outcome of half-ICSI patients with fresh embryo-transfer cycles.
| Characteristic | IVF | ICSI | IVF+ICSI |
|---|---|---|---|
| Fresh embryo transfer cycles | 363 | 274 | 247 |
| No. fresh embryo transferred |
2.0 ± 0.3 | 1.9 ± 0.5 | 2.2 ± 0.4 |
| Age (y) (mean ± STD) | 32.5 ± 3.8 | 32.4 ± 4.1 | 33.0 ± 4.5 |
| Live birth: no. (%) | 164 (45.2) | 114 (41.6) | 100 (40.5) |
| Singleton live birth per woman | 115 (31.7%) | 86 (31.4%) | 71 (28.7%) |
| Twin live birth per woman | 49 (13.5%) | 28 (10.2%) | 29 (11.8%) |
| Biochemical pregnancy: no. (%) | 233 (64.2) | 147 (53.6)a | 137 (55.5)b |
| Clinical pregnancy: no. (%) | 200 (55.1) | 132 (48.2) | 120 (48.6) |
| Preterm birth [no./total no. (%)] | 11/164 (6.7) | 9/114 (7.9) | 6/100 (6.0) |
| Neonatal abnormalities [no./total no. (%)] | 5/213 (2.3) | 4/142 (2.8) | 2/129 (1.6) |
Values are presented as number (%).
aP<0.05 ICSI compared to IVF groups.
bP<0.05 IVF+ICSI compared to IVF groups.
Clinical outcome of primary infertility and secondary infertility half-ICSI patients with fresh embryo-transfer cycles.
| Primary infertility (608 cycles) | Secondary infertility (276 cycles) | |||||
|---|---|---|---|---|---|---|
| Characteristic | IVF | ICSI | IVF+ICSI | IVF | ICSI | IVF+ICSI |
| Fresh embryo transfer cycle: no. (%) | 244 (40.1) | 201 (33.1) | 163 (26.8) | 119 (43.1) | 73 (26.4) | 84 (30.4) |
| No. fresh embryo transferred per cycle (mean ± STD) | 2.0 ± 0.3 | 1.9 ± 0.4 | 2.1 ± 0.3 | 2.0 ± 0.2 | 1.9 ± 0.5 | 2.2 ± 0.4 |
| Age (y) (mean ± STD) | 32.0 ± 3.7 | 31.9 ± 4.0 | 32.7 ± 4.5 | 33.6 ± 3.8 | 33.7 ± 4.0 | 33.8 ± 4.5 |
| Live birth: no. (%) | 107 (43.9) | 86 (42.8) | 66 (40.5) | 57 (47.9) | 28 (38.4) | 34 (40.5) |
| Singleton live birth per woman | 75 (30.7%) | 65 (32.3%) | 48 (29.4%) | 40 (33.6%) | 21 (28.8%) | 23 (27.4%) |
| Twin live birth per woman | 32 (13.2%) | 21 (10.5%) | 18 (11.1%) | 17 (14.3%) | 7 (9.6%) | 11 (13.1%) |
| Biochemical pregnancy: no. (%) | 155 (63.5) | 111 (55.2) | 97 (59.5) | 78 (65.5) | 36 (49.3)a | 40 (47.6)b |
| Clinical pregnancy: no. (%) | 135 (55.3) | 100 (49.8) | 81 (49.7) | 65 (54.6) | 32 (43.8) | 39 (46.5) |
| Preterm birth: [no./total no. (%)] | 6/107 (5.6) | 5/86 (5.8) | 3/66 (4.5) | 5/57 (8.8) | 4/28 (14.3) | 3/34 (8.8) |
| Neonatal abnormalities: [no./total no. (%)] | 5/139 (3.6) | 3/107 (2.8) | 2/84 (2.4) | 0/74 (0.0) | 1/35 (2.9) | 0/45 (0.0) |
Values are presented as number (%).
aP<0.05 ICSI compared to IVF groups.
bP<0.05 IVF+ICSI compared to IVF groups.
A total of 89 cycles (7.9%) with complete IVF fertilization failure showed a low second polar body expulsion (2PB) rate (33.6%) after a 5-h short-time fertilization period, which included 34 cycles (3.0%) with no 2PB oocytes observed in the IVF group. The 2PN rate, high-quality embryo rate and utilized oocyte rate of ICSI embryos were 71.1%, 62.9%, and 45.0%, respectively. The live birth rate, biochemical pregnancy rate, clinical pregnancy rate, preterm birth rate, nd the neonatal abnormality rate were 47.1%, 60%,55.7%, 3.0%, and 4.9%, respectively (
Embryo and clinical outcome of 89 cycles of complete IVF infertility failure.
| Characteristic | IVF | ICSI |
|---|---|---|
| No. of matured oocytes | 417 | 478 |
| 2PN: no. (%) | 0 | 340 (71.1) |
| High-quality embryo: no. (%) | 0 | 214 (62.9) |
| No. of embryos transferred | 0 | 124 |
| No. of vitrified embryos | 0 | 91 |
| Utilized oocytes: no. (%) | 0 | 215 (45.0) |
| Fresh embryo transfer cycle | 0 | 70 |
| Live birth: no. (%) | – | 33 (47.1) |
| Singleton live birth per woman | – | 25 (35.7%) |
| Twin live birth per woman | – | 8 (11.4%) |
| Biochemical pregnancy: no. (%) | – | 42 (60) |
| Clinical pregnancy: no. (%) | – | 39 (55.7) |
| Preterm birth: [no./total no. (%)] | – | 1/33 (3.0) |
| Neonatal abnormalities: [no./total no. (%)] | – | 2/41 (4.9) |
| Second polar body expulsion: no. (%) | 140(33.6) |
Oocyte fertilization is a complex process affected by a series of factors, including state of oocyte maturation, sperm maturation, and vitality or fusion of genetic material. Any abnormality in these steps leads to fertilization failure. For oligozoospermia and asthenozoospermia patients, ICSI greatly improves oocyte fertilization rate. In recent years, several studies have found that ICSI fertilization can also be effective in improving the fertilization rate of patients with unexplained infertility (
For secondary infertility patients, ICSI only resulted in a significantly higher 2PN rate compared with IVF. The high-quality embryo rate and the utilized oocyte rate did not differ between IVF and ICSI groups. Moreover, ICSI embryos had a lower biochemical pregnancy rate. Therefore, according to our results, ICSI is not necessary for secondary infertility patients. Furthermore, the ICSI procedure may decrease embryo implantation capacity.
ICSI was first used for male-factor infertility, but in recent years, it has also been used in non-male-factor infertility cycles (
Short-time insemination and immediate rescue ICSI have been widely used in recent years, which has decreased complete fertilization failure. ICSI can be performed on oocytes that do not discharge a second polar body within 4–6 hours post-insemination (
This retrospective study had a large sample size and was conducted at one IVF laboratory. The laboratory results were valuable in comparing the effect of ICSI and IVF treatment for sibling oocytes. However, based on the benefit to patients, the embryo transfer selection order decreased the clinical significance of this study. A further study on cumulative pregnancy rate in the future may provide more conclusive answers. A second limitation was the absence of exclusively IVF or exclusively ICSI matched groups based on the same infertility factors. Hence, further studies, including prospective, randomized, controlled trials, are required to evaluate the clinical significance of half-ICSI.
In conclusion, this study demonstrated that half-ICSI insemination may be successful for primary infertility patients; however, for secondary infertility patients, ICSI is not necessary and may be an excessive intervention. For patients with a lower fertilization failure rate in conventional IVF, the use of short-time insemination and rescue ICSI would be key. With concern for the safety of ART, we suggest that half-ICSI is not necessary for patients with normal semen and that ICSI should be used with more caution.
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
The studies involving human participants were reviewed and approved by the Ethics Committee of Center for Reproductive Medicine, Cheeloo College of Medicine, Shandong University.
ML put forward the study question and designed the research. NP analyzed the data. NP and SM drafted the manuscript and ML revised it critically. All authors were involved in the acquisition of data and have approved the version to be published.
The National Natural Science Foundation of China (81401266), The National Natural Science Foundation of China (82171842) and the Natural Science Foundation of Shandong Province (ZR2013HQ053). The funding sources had no role in the study design, collection, analysis, or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
We thank all the participants of this study. We also thank all research staff at the Center for Reproductive Medicine, Cheeloo College of Medicine, Shandong University, for their cooperation throughout the study.
The Supplementary Material for this article can be found online at: